mutated Ligand Binding Site gene DataBase





About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for CRAT
Gene summary
Basic gene Info.Gene symbolCRAT
Gene namecarnitine O-acetyltransferase
CytomapUCSC genome browser: 9q34.1
Type of geneprotein-coding
DescriptionCATcarnitine acetylasecarnitine acetyltransferase
Modification date20141211
dbXrefs MIM : 600184
Ensembl : ENSG00000095321
HPRD : 08971
Vega : OTTHUMG00000147343
ProteinUniProt: P43155
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_CRAT
BioGPS: 1384
PathwayNCI Pathway Interaction Database: CRAT
Pathway Commons: CRAT
ContextiHOP: CRAT
ligand binding site mutation search in PubMed: CRAT
UCL Cancer Institute: CRAT
Assigned class in mutLBSgeneDBC: This gene just belongs to mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO:0019254carnitine metabolic process, CoA-linked15099582

Ligand binding site mutations for CRAT

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.

Protein structure related information for CRAT
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for CRAT from PDB

Differential gene expression and gene-gene network for CRAT
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of CRAT and the right PPI network was created from samples without mutations in the LBS of CRAT. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Phenotype information for CRAT
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Pharmacological information for CRAT
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure
ApprovedDB00583L-CarnitineSmall molecule
NutraceuticalDB01992Coenzyme ASmall molecule
ExperimentalDB02648(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-AmmoniumSmall molecule

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of CRAT go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS

Conservation information for LBS of CRAT
Multiple alignments for P43155 in multiple species
LBSAA sequence# speciesSpecies
E347EHAAAEGPPIV3Homo sapiens, Mus musculus, Rattus norvegicus
E347EHSKMDGTPTL1Saccharomyces cerevisiae (strain ATCC 204508 / S288c)
F566DCVMFFGPVVP2Homo sapiens, Mus musculus
F566FDGYGWSQVND1Saccharomyces cerevisiae (strain ATCC 204508 / S288c)
F566DCVMSFGPVVP1Rattus norvegicus
H343GMVYEHAAAEG2Mus musculus, Rattus norvegicus
H343GLVYEHAAAEG1Homo sapiens
H343GFLAEHSKMDG1Saccharomyces cerevisiae (strain ATCC 204508 / S288c)
S454CATYESASLRM3Homo sapiens, Mus musculus, Rattus norvegicus
S454LPTYEAASTRK1Saccharomyces cerevisiae (strain ATCC 204508 / S288c)
S552MHFNLSTSQVP2Mus musculus, Rattus norvegicus
S552MHFHLSTSQVP1Homo sapiens
S552STWLISTSQLS1Saccharomyces cerevisiae (strain ATCC 204508 / S288c)
T465FHLGRTDTIRS3Homo sapiens, Mus musculus, Rattus norvegicus
T465YFKGRTETGRS1Saccharomyces cerevisiae (strain ATCC 204508 / S288c)
T553HFNLSTSQVPA2Mus musculus, Rattus norvegicus
T553HFHLSTSQVPA1Homo sapiens
T553TWLISTSQLSS1Saccharomyces cerevisiae (strain ATCC 204508 / S288c)
V569MFFGPVVPDGY2Homo sapiens, Mus musculus
V569YGWSQVNDNGF1Saccharomyces cerevisiae (strain ATCC 204508 / S288c)
V569MSFGPVVPDGY1Rattus norvegicus
W102WLSEWWLKTAY3Homo sapiens, Mus musculus, Rattus norvegicus
W102WMAKFWDEQSY1Saccharomyces cerevisiae (strain ATCC 204508 / S288c)
Y452QACATYESASL3Homo sapiens, Mus musculus, Rattus norvegicus
Y452RQLPTYEAAST1Saccharomyces cerevisiae (strain ATCC 204508 / S288c)

Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas